P/E ratio for Sinopharm (1099.HK)
P/E ratio at the end of 2022: 6.41
According to Sinopharm's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 7.21865. At the end of 2022 the company had a P/E ratio of 6.41.
P/E ratio history for Sinopharm from 2009 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 6.41 | 17.28% |
| 2021 | 5.47 | -17.02% |
| 2020 | 6.59 | -45.23% |
| 2019 | 12.0 | -13.26% |
| 2018 | 13.9 | -7.33% |
| 2017 | 15.0 | -11.43% |
| 2016 | 16.9 | -10.03% |
| 2015 | 18.8 | -3.44% |
| 2014 | 19.4 | 0.02% |
| 2013 | 19.4 | -18.75% |
| 2012 | 23.9 | 5.26% |
| 2011 | 22.7 | -47.83% |
| 2010 | 43.6 | -4.59% |
| 2009 | 45.7 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.